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Polychlorinated biphenyl (PCB) mixtures
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The endocrine-disrupting actions ofchlori-
nated aromatic chemicals are well known,
and concern has recently heightened
because oftheir ubiquitous presence in the
environment and in food (1). Toxicody-
namics, i.e., agonist-receptor interactions
(2), play a critical role in endocrine disrup-
tion; however, particularly for xenobiotics,
which are enzyme inducers and/or yield
bioactive metabolites, toxicokinetics play
an equally critical role. Neither residues of
parent xenobiotic in the target tissue nor
affinity for the target receptor alone can
reliably predict toxicity. Integrated toxico-
dynamic and toxicokinetic considerations
are essential to meaningful risk assessment.
Polychlorinated biphenyls (PCBs) are
persistent global pollutants with a net
estrogenic activity in most mixtures (3-5),
even though a few of the 209 possible
chlorobiphenyl (CB) congeners, namely,
the coplanar Ah receptor agonists, are
antiestrogenic under some conditions
(5,6). The biological activities ofAh recep-
tor agonists can generally be predicted
based on their induction ofhepatic micro-
somal ethoxyresorufin O-dealkylase
(EROD; P4501A1) as compared to
2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD), the most potent Ah receptor
agonist (7). The environmentally more
abundant ortho-chlorinated congeners are
nonplanar and generally poor ligands for
theAh receptor. Di- and tri-ortho-chlorinated
congeners generally show a phenobarbital-
type pattern of monooxygenase induction
and induction potencies can be compared
by measuring pentoxyresorufin O-dealky-
lase (PROD; P4502B1) (7). Some mono-
ortho CBs are "mixed" inducers, causing
elevation ofboth EROD and PROD activ-
ities (7). Phase 2 conjugating enzymes are
also differentially induced.
Microsomal monooxygenases and
phase 2 conjugating enzymes play a pivotal
role in PCB toxicoses. Not only are these
enzymes differentially induced by different
CB congener types, but the CB congeners
as well as endogenous hormones are differ-
entially metabolized by the various
isozymes (8). Some hydroxy CB metabo-
lites may have enhanced uterotropic poten-
cy (3,9). At the same time, other metabo-
lites may inhibit P450 activity in vitro (10)
or depress P450 activity in vivo (11,12),
probably through downregulation of syn-
thesis. The methyl sulfonyl metabolites
(which are not generated in tissue culture
systems) can also induce P450s (12), but
they may inhibit the activity of TCDD-
induced P450s in human cell lines (13).
Therefore, subtle differences in toxicoki-
netics may be impossible to extrapolate from
independent structure-activity relationships,
and the net effect of different chemicals on
endocrine functions may be even more elu-
sive. The demonstration that two consecutive
doses of a specific CB or PCB mixture are
more effective than a single larger total dose
(5) raises the possibility that the initial dose
may induce monooxygenases that enhance
the bioactivation of the second dose to a
more potent estrogen. On the other hand, if
the initial CB merely acts as a priming dose
(as with estradiol), the induction of mono-
oxygenases and, especially phase 2 conjugat-
ing enzymes, would be expected to attenuate
theestrogenic action.
Parallel assessment ofestrogenicity and
monooxygenase induction might suggest
further interactions between biotransfor-
mation and endocrine disruption. The pre-
pubertal rat is a sensitive model for estro-
genicity if short-term studies, completed
before puberty, are required. Acute
responses were considered more useful for
determining primary actions and interac-
tions because final toxic outcomes after
longer dosing and/or observation periods
are complicated by endocrine responses to
disruption, other repair responses, progres-
sion ofinitial changes to other pathologies,
and more complicated toxicokinetics. The
sensitivity ofthe model to estrogenic PCBs
is enhanced by dividing the dose over 2
days (5), but it was unclear how further
modifications between weaning and puber-
ty might affect the sensitivity; furthermore,
integration ofenzyme induction and other
toxicokinetic factors into the model
required additional time-response consid-
erations.
Materials and Methods
We selected two persistent nonplanar con-
geners that have different potencies for
inducing P4502B1. CB 153 (2,2',4,4',5,5'-
hexaCB), recently reported to be estrogenic
in the divided-dose protocol (14), and CB
47 (2,2'4,4'-tetraCB), which was reported
to have little estrogenic activity in the sin-
gle-dose protocol (15), were compared in
2-day and 5-day dosing regimens. Aroclor
1242, a moderate mixed inducer of
monooxygenases (7,14), is estrogenic in
immature rats in both single-dose and dou-
ble-dose protocols (2-4;14,15); we used
this mixture as a reference toxicant to
determine the effect of the 5-day dosing
protocol on uterotropic and monooxyge-
nase induction activities.
Female Sprague-Dawley rats nursing
litters of9-11 female pups were purchased
from Harlan Sprague-Dawley (Indianapolis,
Indiana) and shipped when the litters were
10-15 days of age. At 20 days of age, the
pups were weaned, weighed, and separated
into dosage groups divided as evenly as
possible among litters. Pups were dosed
intraperitoneally with PCBs in 0.1 ml corn
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oil. A positive control (1 pg estradiol in 0.1
ml corn oil) was included from most litters,
and a negative control (corn oil alone) was
included from all litters. In the 2-day pro-
tocol, we dosed pups on days 20 and 21 of
age and killed them on day 22; a limited
experiment postponed weaning until day
21, and the rats were killed on day 23. In
the 5-day protocol pups were dosed on
days 23 and 24, days 20, 22, and 24, or
days 20, 21, 22, 23, and 24 and killed on
day 25. Positive and negative controls
received the three-dose treatment protocol.
One day after the last dose, weweighed
pups, decapitated them and collected
blood from the cervical stump. The repro-
ductive tract was removed and the uterus
trimmed of adhering fat and connective
tissue and weighed. The liver was perfused
in situ with ice-cold Tris-KCl (0.05 M
Tris-HCl at pH 7.4 + 0.15 M KCl),
removed, weighed, divided into two equal
portions and homogenized by hand in
Tris-KCl. We resuspended microsomes
prepared from the 10-12% homogenates
and stored them at -800C until further
dilution and assay for protein, EROD, and
PROD (14). For rats killed on day 25, the
uteri were homogenized by hand in 1.0 ml
Tris bufferandanalyzed forprotein content.
Blood was allowed to clot, and serum
was decanted and stored at -200C until
analyzed for PCB residues by hexane-ace-
tone extraction, sodium sulfate dehydra-
tion, and GLC (14). Recoveries from seed-
ed samples were 100.24% ± 0.01% for CB
47 and 98.78% ± 1.30% for CB 153. For
some animals, we also removed 100 pl of
the liver homogenate and stored it at
-20°C for PCB analysis (recovery = 96.3%
± 4.2%).
Results
Estradiol clearly increased uterine weights
and protein content in prepubertal female
rats whether administered on days 20 and
21, or days 20, 22, and 24 (Table 1). A
total dose of 120 mg/kg Aroclor 1242 sig-
nificantly increased absolute uterus weights
and protein content, but relative uterus
weights were only marginally different
from controls (p>0.10). CB 47 significant-
ly increased uterine weights in the 2-day
protocol, and the difference was slightly
greater in rats killed on day 23; however,
CB 47 was less effective in the more vari-
able rats killed on day 25 in which only
uterine protein was significantly increased
(Table 1). Two 30 mg/kg doses ofCB 153
had a similar effect in 22-day-old rats and
25-day-old rats if two extreme outliers are
censored from the 25-day-old rats; howev-
er, reducing n to 3 made it difficult to
establish significance in the 25-day-old
rats (Table 1). A total dose of 50 mg/kg
CB 153 divided between days 20 and 21
Table 1. Uterotropic effectof PCBs in immature female rats aftervarious dosing regimens
Uterine wetweight Protein
Treatment(dose xdays)" n mg mg/g bodyweight (mg/uterus)
Killed day22
Corn oil (0.1 ml x2) 5 32.8 ± 2.4 0.71 ± 0.06 ND
Estradiol (20 pg/kg x 2) 5 73.8 ± 3.5** 1.47 ± 0.09** ND
CB 47 (30 mg/kg x2) 7 47.2 ± 3.0* 0.91 ± 0.05* ND
CB 153(30 mg/kg x2) 7 40.2 ±2.7t 0.78 ± 0.06 ND
Killed day23
Corn oil (0.1 ml x 2) 5 37.6 ± 3.4 0.81 ± 0.06 ND
CB 47(30 mg/kg x2) 5 52.9 ± 2.4* 1.16 ± 0.08* ND
Killed day 25
Corn oil (0.1 ml x3) 7 43.1 ± 2.2 0.70 ± 0.03 2.94 ± 0.25
Estradiol (20 pg/kg x3) 4 60.1 ± 4.2** 0.98 ± 0.04** 4.19 ± 0.51*
CB 47 (30 mg/kg x 5) 6 48.3 ± 3.8 0.71 ± 0.06 3.93 ± 0.42*
CB 153(12 mg/kg x5) 5 45.7 ± 4.4 0.71 ± 0.08 3.43 ± 0.28
CB 153(20 mg/kg x3) 5 44.3 ±2.6 0.72 ± 0.04 3.39± 0.38
CB 153(30 mg/kg x2) 5C 56.7 ± 11.8 0.85 ± 0.15 4.86 ± 0.70*
Aroclor 1242 (24 mg/kg x5) 5 52.2 ± 3.3* 0.83 ± 0.06 4.33 ± 0.36*
Aroclor 1242(40 mg/kg x3) 5 49.1 ± 2.2* 0.83 ± 0.05 4.62 ± 0.16*
Aroclor 1242(60 mg/kg x 2) 5 50.8 ± 2.7* 0.84 ± 0.04 3.92 ± 0.24*
ND, not determined.
"Doses administered intraperitoneally either 2 successive days before termination, 3 alternate days
beforetermination, or5 successive days before termination.
bValues are means ± SEM. Data were analyzed by Dunnett's test for multiple comparison in three sepa-
rate data sets as determined by age attermination. (*, *, t) Significant (p<0.05) difference from corn oil
controls in each data set; different symbols indicate significant differences from other treatment groups
in the same data set.
CThe large variation was improved by censoring two extreme data points. For n = 3, significant (p<0.05)
increases in uterine weight (48.5 ± 1.6) and uterine protein (4.34 ± 0.07) were demonstrated, but the
increase in relative uterine weight(0.076 ± 0.02) was notsignificantwith the lower n.
Table 2. Liver microsomal protein and ethoxyresorufin O-dealkylase (EROD) and pentoxyresorufin 0-
dealkylase (PROD) activity in immature female rats receiving PCBs in various dosing regimens
Liver Proteinb pmol/min/mgprotein
Treatment (dose xdays)8 n (% body) (mg/g liver) EROD PROD
Killed day22
Corn oil (0.1 ml x2) 5 4.7 ±0.2 8.6 ± 0.9 184 ±40 7.8± 1.3
Estradiol (20 pg/kg x2) 4 4.6 ±0.3 10.7 ± 1.5* 169 ±35 6.6± 1.5
CB 47 (30 mg/kg x2) 5 5.1 ±0.2 11.4 ± 1.3* 136 ±29 8.4± 1.9
CB 153(30 mg/kg x2) 5 4.9 ± 0.2 12.2 ± 1.6* 161 ± 37 14.0 ± 3.2*
Killed day 23
Corn oil (0.1 ml x2) 5 4.6 ± 0.1 13.9± 1.4 167 ± 17 8.2± 0.7
CB 47(30 mg/kg x2) 5 4.9± 0.1 14.3 ± 1.1 312 ± 28* 17.7 ± 1.7*
Killed day25
Corn oil (0.1 mlx3) 6 5.3±0.1 11.1 ±0.4 95±1 4.7 ±0.3
Estradiol (20 pg/kg x3) 4 5.2± 0.1 12.3 ± 1.5 108 ±7 6.5± 1.0
CB 47 (30 mg/kg x5) 4 5.9 ±0.2* 16.6 ± 2.0* 90 ± 4 23.8 ± 5.7*
CB 153(12mg/kg x5) 5 5.7 ± 0.1* 16.4 ± 1.6* 120 ± 8 32.5 ± 5.7*
CB 153 (20 mg/kg x3) 5 5.8 ± 0.2* 15.0 ± 1.5* 120 ± 6 33.0 ± 6.8*
CB 153(30 mg/kg x2) 5 5.4± 0.1 16.0±1.7* 110±14 35.0 ±10.1 Aroclor 1242(24 mg/kg x5) 3 5.5 ± 0.1* 15.0 ±0.2* 883 ± 77* 7.4 ± 0.6
Aroclor 1242(40 mg/kg x3) 3 5.8 ± 0.2* 14.6 ± 0.7* 949 ± 93* 9.5 ±0.6t
Aroclor 1242(60 mg/kg x2) 3 5.5 ±0.1* 13.3 ± 1.4 1072 ± 116* 9.5 ± l.O0
"Doses were administered intraperitoneally either 2 successive days before termination, 3 alternate days
beforetermination, or 5 succesive days beforetermination.
b\Values are means ± SEM. (*, t) Significant (p<0.05) differences from corn oil controls in each each data
set (as determined by termination age); different symbols indicate significant differences from other.
treatment groups inthe same data set.
has previously been shown to produce a
peak uterotropic effect; declining effectwas
associated with increased PROD activity at
100 mg/kg, and both effect and PROD
activity were lower at 120 mg/kg (14).
The high variability for CB 153 could be
partly due to apparent steep time-response
and dose-response U-shaped relationships
influenced by toxicokinetics and must be
examined moreclosely.
Induction of hepatic EROD activity
was not apparent in rats treated with either
CB except for a slight increase in 23-day-
old rats after CB 47 treatment (Table 2).
Aroclor 1242 increased EROD activity 9-
to 10-fold in 25-day-old rats, regardless of
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the schedule for delivering the total dose of
120 mg/kg.
Again, the division of the total dose
over 5 days did not significantly influence
induction ofPROD by CB 153 or Aroclor
1242; PROD activity was induced about
five-fold by a total dose of 150 mg/kg CB
47 or 60 mg/kg CB 153, but only about
two-fold by 120 mg/kg Aroclor 1242
(Table 2). Induction ofPROD activity was
less pronounced in slightly younger rats.
CB 153 only doubled PROD specific
activity when administered at the same
dose on days 20 and 21. PROD activity
was not changed by 30 mg/kg CB 47 on
days 20 and 21, but was doubled when
dosing was delayed to days 21 and 22
(Table 2).
Residues of the two persistent CBs in
the serum were high (up to 22 jig/ml) 1
day after the last of multiple intraperi-
toneal doses (Table 3). CB 47 residues
were equal the day after two intraperi-
toneal doses of 30 mg/kg whether the
doses were administered on days 20 and 21
or days 21 and 22 (Table 3). The serum
residues after five daily doses of 30 mg/kg
CB 47 were twice that ofresidues after two
daily doses and more variable. Residues
were higher in rats with lower total PROD
activity (specific activity x mg protein/g
liver x g liver) than in rats with greater
than twofold higher PROD activity (Fig.
1). This relationship among individual rats
was not apparent after two daily doses.
As with CB 47, five daily doses of CB
153 resulted in higher and more variable
serum residues than two or three higher
doses (Table 3). Greater total PROD activ-
ity also tended to be associated with lower
PCB residues in rats given five daily doses
of 12 mg/kg CB 153, but the relationship
was not as clear as with CB 47 (Fig. 1);
moreover, in rats administered the higher
dose on days 23 and 24, the more likely
direct relationship between serum CB and
PROD activity is seen (Fig. 2). Neither
pattern was readily discernable in 22-day-
old rats or in 25-day-old rats receiving
doses on alternate days; nevertheless, dif-
ferences in PROD induction contributed
to the variability of serum residues or vice
versa.
Discussion
CBs 47 and 153 are slowly metabolized
mainly by PROD and/or other phenobar-
bital-induced monooxygenases (8). Small
amounts of CB 153 metabolites are tran-
siently (2 hr) present in monkey liver, and
much larger amounts persist considerably
longer in dog liver (8). The basal biotrans-
formation potential of the rat is between
that ofthe dog (very high) and the monkey
(very low) and can be at least doubled by
phenobarbital induction (8). During the
longer exposure (5 days) in the current
study, induced PROD as well as induced
phase 2 enzymes should be expected to
favor lower serum residues ofparent com-
pound; however, the apparent rapid
decline ofPROD activity toward basal lev-
els after relatively recent declines in parent
CB requires further explanation. With
highly induced PROD, the concentration
of metabolites in the liver would be
increased; because free hydroxylated CBs
have been shown to inhibit some
monooxygenase activities (10), this might
explain the more-abrupt-than-expected
decrease in measured PROD activity.
In older animals with a larger body fat
compartment, CB 153 redistribution to
other tissues (rather than metabolism) may
be responsible for lower serum residues
(16,17) and limit exposure to hepatic
enzymes (17); however, in these immature
rats with less body fat as well as less time
for equilibria to occur, serum residues are
relatively predictive ofliver residues (Fig. 3).
The increased inducibility ofPROD in
25-day-old rats on the two-dose CB 153
protocol compared to 22-day-old rats
introduces greater variability in PROD
induction (Table 2). The short-term dos-
ing does not permit stabilization of the
high PROD-low serum CB relationship
suggested in Figure 1. In fact, in rats dosed
on days 23 and 24, variability is great
enough to clearly show the more expected
direct relationship (Fig. 2). This variability
is also reflected in the uterotropic effect
(Table 1), but the greatest increase in
uterus weight (to 103 mg) was in the rat
with the lowest total PROD activity (and
lowest serum parent CB level), whereas the
rat with the higher serum residues had a
uterus that weighed the same as the lower
controls (35 mg). Although closer scrutiny
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Figure 1. Inverse relationship between pentoxyre-
sorufin O-dealkylase activity and serum chloro-
biphenyl residues in 25-day-old rats dosed with 30
mg/kg CB 47 or 12 mg/kg CB 153 on days 20, 21,
22, 23, and 24.
Table3. Determination of average actual doses and terminal serum residues in immature female rats
receiving PCBs in various dosing regimens
Treatmenta (dose xdays) n Actual doseb(mg/kg) Serum residue(pg/ml)
Killed day 22
CB 47(30 mg/kg x2) 4 62.1 ± 1.7 10.94 ± 1.40
CB 153 (12 mg/kg x2)c 4 21.9 ± 0.4 2.97 ± 1.66c
CB 153(24 mg/kg x2)c 4 49.2 ± 1.4 2.89 ±2.38c
CB 153(30 mg/kg x2) 7 61.5 ±2.4 11.79 ± 1.68
CB 153(50 mg/kg x2)c 4 103.0 ± 5.4 13.38 ±7.50C
CB 153(60 mg/kg x2)c 4 118.6 ± 5.4 5.22 ± 2.27c
Killed day 23
CB 47 (30 mg/kg x2) 5 69.9 ± 3.4 10.79 ± 0.28
Killed day 25
CB 47 (30 mg/kg x5) 6 130.9 ± 3.5 22.26 ± 5.43
CB 153 (12 mg/kg x 5) 5 54.9 ± 1.0 18.86 ± 10.08
CB 153 (20 mg/kg x3) 5 56.7 ± 2.0 7.58 ± 0.99
CB 153 (30 mg/kg x2) 5 53.7 ± 1.6 8.09 ± 1.62
8Nominal doses administered intraperitoneally either 2 successive days before termination, 3 alternate
days beforetermination, or 5 successive days before termination.
bActual dose determined by dividing confirmed (byGLC) dose by average weight during dosing period.
CSASCO Sprague-Dawley rats from previous study(14).
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Figure 2. Direct relationship between pentoxyre-
sorufin 0-dealkylase activity and serum chloro-
biphenyl 153 residues in 25-day-old rats dosed
with 30 mg/kg CB 153 on days 23 and 24.
Environmental Health Perspectives
a
570A - * - 9-.-
55
44
a10
22
l3 ll
11
0 5 10 15 20 25
Serum residue (ppm)
44
0.
55
33.
I
22
L I 1 10
Serum residue (ppm)
Figure 3. Relationship between serum and liver chlorobiphenyl residues in individual 22-day-old rats
given 11, 25, or 51 mg/kg CB 153 on days 20 and 21. The data were fit by (A) linear regression and (B) the
exponential equation: Liver residue = aesal)4IoG serum residue. Correlation coefficients for the data were virtu-
ally equal (0.9586 for linear versus 0.9587 for exponential).
with a larger number of animals may be
necessary, these large ranges after shorter
times in highly induced rats indicate rather
steep time-response curves for both toxico-
kinetics and physiological actions.
Increased uterotropic potency from
divided doses (5) may be due to induced
PROD activity and the generation ofmore
bioactive (9) metabolites in the liver (8).
Phase 2 enzymes such as uridine diphos-
phate-glucuronyl transferases (Li M-H,
Hansen LG, unpublished results) and
glutathione transferases (Gillette J,
Dauterman WC, personal communica-
tion) were also induced in these rats.
Therefore, enhanced phase 2 metabolism
competes with enhanced bioactivation in
an already complex system so that the
increased variability observed should have
been expected.
When these relationships are consid-
ered collectively, it becomes apparent that
developmental differences in toxicokinetics
and toxicodynamics interact profoundly
with dose selection, frequency, and timing
so that narrow windows of response are
created. If these whole-animal considera-
tions are not fully explored, inaccurate and
misleading conclusions may be reached
that will seriously impede effective risk
assessment.
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